Thayer C, Bartlett S T, Ward R E
Department of Surgery, University of California, Davis School of Medicine, Sacramento 95817.
Am J Surg. 1990 Dec;160(6):614-7. doi: 10.1016/s0002-9610(05)80756-1.
In 152 renal transplant recipients, the results of immunosuppression with three-drug sequential (Minnesota antilymphocyte globulin, prednisone, azathioprine, and cyclosporine) immunosuppression (n = 107) were compared with those of a two-drug sequential protocol (Minnesota antilymphocyte globulin, prednisone, and cyclosporine) that excluded azathioprine (n = 45). The study groups were comparable by age, sex, etiology of renal failure, incidence of diabetes, and degree of HLA matching. Patient survival at 1 year was not significantly different in the two groups (two drug, 93% versus three drug, 86%; p = 0.19). One-year graft survival was superior in the two-drug group (two drug, 93% versus three drug, 75%; p = 0.02). Analysis of primary transplants only (n = 116) yielded the same results. During the first year, the serum creatinine level remained stable in both groups. As expected, the three-drug therapy group had significantly more bacterial and viral infections. For low-risk primary cadaveric renal transplants, two-drug sequential immunosuppression is superior.
在152名肾移植受者中,对采用三联序贯免疫抑制疗法(明尼苏达抗淋巴细胞球蛋白、泼尼松、硫唑嘌呤和环孢素)的107名患者与采用不含硫唑嘌呤的二联序贯方案(明尼苏达抗淋巴细胞球蛋白、泼尼松和环孢素)的45名患者的免疫抑制效果进行了比较。研究组在年龄、性别、肾衰竭病因、糖尿病发病率和HLA匹配程度方面具有可比性。两组患者1年时的生存率无显著差异(二联疗法组为93%,三联疗法组为86%;p = 0.19)。二联疗法组的1年移植物生存率更高(二联疗法组为93%,三联疗法组为75%;p = 0.02)。仅对初次移植(n = 116)进行分析也得出了相同的结果。在第一年,两组患者的血清肌酐水平均保持稳定。正如预期的那样,三联疗法组的细菌和病毒感染明显更多。对于低风险的初次尸体肾移植,二联序贯免疫抑制疗法更优。